Biochemical recurrence after definitive prostate cancer therapy. Part II: Treatment strategies for biochemical recurrence of prostate cancer*
Authors:
- John F WardJWJohn F Ward
- Judd W MoulJMJudd W Moul
- 1 May 2005
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Urology
- Vol. 15 (3) , 187-195
Abstract
Through the prostate-specific antigen era, the proportion of men less than 55 years old with newly diagnosed prostate cancer more than doubled to almost 15%. As increasing numbers of men are living longer with prostate cancer, larger proportions will eventually present to our collective practices with rising prostate-specific antigen levels. Such prostate-specific antigen relapses, conservatively estimated to affect approximately 50 000 men each year, have become the most common form of advanced prostate cancer in the current period. Increasing evidence suggests that early hormonal therapy improves progression-free survival and may alter the cancer-specific survival. However, there is a cost to pay in side-effects when androgen deprivation is administered over prolonged periods. The non-steroidal anti-androgen bicalutamide may offer an equivalent progression-free survival to castration without the complications of androgen deprivation. Observational data seem to indicate that high-risk individuals (i.e. those with high-grade, high-stage disease or a prostate-specific antigen doubling time less than 12 months) may also receive benefit from early therapy. The definition of advanced prostate cancer has changed. Multimodal therapy improves cancer-specific outcomes especially in men with high-risk disease. The potential opportunities for novel therapeutic agents with low associated morbidity are great.Keywords
This publication has 58 references indexed in Scilit:
- Predictors of Biochemical Outcome With Salvage Conformal Radiotherapy After Radical Prostatectomy for Prostate CancerJournal of Clinical Oncology, 2003
- Salvage radiotherapy for rising or persistent PSA after radical prostatectomyUrology, 2002
- Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factorsUrology, 2002
- Prediction of Response to Salvage Radiation Therapy in Patients With Prostate Cancer Recurrence After Radical ProstatectomyJournal of Clinical Oncology, 2001
- Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 yearsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000
- RADIOTHERAPY FOR ISOLATED SERUM PROSTATE SPECIFIC ANTIGEN ELEVATION AFTER PROSTATECTOMY FOR PROSTATE CANCERJournal of Urology, 2000
- Consensus Statements on Radiation Therapy of Prostate Cancer: Guidelines for Prostate Re-Biopsy After Radiation and for Radiation Therapy With Rising Prostate-Specific Antigen Levels After Radical ProstatectomyJournal of Clinical Oncology, 1999
- Preirradiation PSA predicts biochemical disease-free survival in patients treated with postptrostatectomy external beam irradiationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997
- The Use of Radiotherapy for Patients with Isolated Elevation of Serum Prostate Specific Antigen Following Radical ProstatectomyJournal of Urology, 1996
- The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigenInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995